Fly News Breaks for May 29, 2019
May 29, 2019 | 08:51 EDT
Northland analyst Carl Byrnes initiated Opiant Pharmaceuticals with an Outperform and $42 price target given its established track record developing NARCAN for opioid overdose. Byrnes believes Opiant's valuation "woefully" understates the company's extensive pipeline, NARCAN royalty stream, government-based funding of key programs, and cash.
News For OPNT From the Last 2 Days
There are no results for your query OPNT